The US Supreme Court Denies Sandoz’s Petition for Erelzi (biosimilar, etanercept)

 The US Supreme Court Denies Sandoz’s Petition for Erelzi (biosimilar, etanercept)

Shots:

  • The US Supreme Court has denied Sandoz’ petition to review Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi (etanercept-szzs) for the reference product, Enbrel (etanercept)
  • The company was unable to launch the product in the US due to patent litigation. The affordable biosimilar will not be available in the US till 2029 to treat autoimmune and inflammatory diseases
  • Erelzi has been approved in the US for more than 4yrs. since Aug’2016

Click here to­ read full press release/ article | Ref: Novartis | Image: Novartis

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post